Recent Updates
Recently added Catalysts
CNSY Positive Sentiment

Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Tuesday, July 21, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Plus Therapeutics has announced a regional coverage agreement with Medical Mutual for its CNSide® cerebrospinal fluid assay, effective July 1, 2026. This agreement aims to improve access to diagnostic services for patients with metastatic CNS cancer. The coverage is expected to enhance treatment options and patient outcomes.

Market Sentiment Analysis

POSITIVE FACTORS

  • Plus Therapeutics secures a regional coverage agreement.
  • The agreement enhances access to CNSide® assay for patients.
  • This move is expected to improve treatment options for metastatic CNS cancer.

Full Press Release Details

HOUSTON, July 21, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today that it has signed a regional agreement with Medical Mutual effective July 1, 2026, covering approximately 1.2

Frequently Asked Questions

What is the CNSide® cerebrospinal fluid assay?

The CNSide® assay is a diagnostic tool used for detecting metastatic CNS cancer.

When does the coverage agreement with Medical Mutual start?

The agreement becomes effective on July 1, 2026.

What does the agreement with Medical Mutual entail?

It provides regional coverage for the CNSide® assay, improving patient access.

Who is Plus Therapeutics?

Plus Therapeutics is a biopharmaceutical company focused on developing treatments for cancer.

ShareAdd on Google
Tags: CNSY Viatris Investor Conferences Healthcare Plus Therapeutics CNSide Medical Mutual CNS cancer diagnostic services
Last updated: Jul 21, 2026

Biotech snapshot

Cash runway
$9M liquidity · $3M/mo burn
~3 mo
High dilution risk